FTSE MIB
33.308,77 -366,38 (-1,09%) Dow Jones
39.150,33 +15,57 (+0,04%) Nasdaq
17.689,36 -32,23 (-0,18%) Nikkei 225
38.596,47 -36,55 (-0,09%) Petrolio
80,64 -0,65 (-0,80%) Bitcoin EUR
60.061,30 -799,94 (-1,31%)
DNLI Sep 2024 30.000 call
| Chiusura precedente | 2,0000 |
| Aperto | 2,0000 |
| Denaro | 0,1500 |
| Domanda | 2,3500 |
| Prezzo d'esercizio | 30,00 |
| Scadenza | 2024-09-20 |
| Min-Max giorno | 2,0000 - 2,0000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 60 |
GlobeNewswireDenali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
Additional biomarker data up to two years of treatment continue to demonstrate rapid and sustained normalization of CSF heparan sulfate to normal healthy levels and improvement in lysosomal function biomarkersAdditional safety data up to two years of treatment continue to demonstrate that DNL310 is generally well toleratedPreviously reported data showed robust and statistically significant reduction of NfL, a marker of neuronal damage, and positive clinical outcome changes in adaptive behavior,
- GlobeNewswire
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the second quarter ended June 30, 2023, and provided business highlights. “In the second quarter, we shared exciting new data demonstrating robust red
